Herpes Zoster Acute Neuralgia: What to Do When Antiepileptic Agents and WHO Step-2 Ladder Therapy Fail to Control Pain
Herpes zoster-associated neuropathic pain (acute herpes zoster neuralgia) is managed through a stepwise approach. When the first treatment line does not achieve the pain-control target after an adequate trial, a defined next-line protocol applies.
Previous line — reason for escalation
The preceding regimen used antiepileptic agents — gabapentin or pregabalin — combined with NSAIDs and opioids per the WHO pain relief ladder (initial treatment at step 2). After 2–4 weeks, pain was not reduced to a level tolerable for the patient on a validated pain intensity scale (VAS or NRS, 0–10), prompting a change in strategy.
Next-line approach (partial overview)
The regimen is modified by introducing a class of tricyclic antidepressant therapy. The complete protocol — including specific agent selection, any additional interventions, and the decision algorithm — is available in the structured evidence-based regimen.
Clinical target
Optimal pain relief, or at minimum reduction to a level the patient can tolerate, measured on a validated pain intensity scale (VAS or NRS, 0–10).
References
- DOI: 10.1111/ddg.14013
- In case of protopathic/neuropathic pain, additional treatment with incremental doses of gabapentin or pregabalin (antiepileptic agents) is recommended; if necessary, this may be combined with an antidepressant (for example, amitriptyline).
- If neuropathic pain does not adequately respond to treatment based on the WHO pain relief ladder, it is recommended to modify the treatment regimen after 2–4 weeks.
- In such cases, it may be recommended to add tricyclic antidepressants (for example, amitriptyline); in case of localized pain and after the skin lesions have healed, capsaicin or lidocaine patches may be recommended.
- The treatment goal with respect to herpes zoster-associated pain should be optimal pain relief or at least pain reduction down to a level tolerable for the patient.
View source ↗